StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) company profile

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)

Close on Nov 17, 2026Market cap $1.58BP/E –Yield –

About Kailera Therapeutics

Pharmaceutical Preparations, SIC 2834

Kailera Therapeutics, Inc. is listed on Nasdaq under the ticker KLRA, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Kailera Therapeutics, Inc.
Headquarters
Waltham, MA
Address
180 Third Avenue, 4th Floor 02451
Phone
(508) 440-9475
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
KLRA
Exchange
Nasdaq
IPO date
Apr 17, 2026
Shares outstanding
130M, Aug 6, 2026
Filer category
<br>Emerging growth company
SEC CIK
2096997
CUSIP
482931102
ISIN
US4829311020
FIGI
BBG01Q3NQQJ1
Share class FIGI
BBG01Q3NQQK9
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ronald C. Renaud JRCEO & President, Director38,094
Nur NicholsonChief Technology Officer–
Kathleen TregoningSee Remarks–
Paul D. BurgessSee Remarks–
Paula CloghessyChief People Officer–
Jamie Beth ColemanChief Commercial Officer–
Scott AkamineChief Legal Officer–
Scott M. WassermanChief Medical Officer–
Douglas W. PaganChief Financial Officer–
Frank ClyburnDirector–
Christopher HiteDirector–
John F. MilliganDirector–
Martin MackayDirector–
Adam KoppelDirector16,875,000
Andrew T. KaplanDirector17,857,143
Yuting LiuDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 17, 2026
Offer price
$16.00
Securities offered
39,062,500
Gross proceeds
$625.00M
Exchange
Nasdaq
First trading day
Apr 17, 2026
First-day close
$26.00+62.5%
Lock-up ends (est.)
Oct 14, 2026

“The public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?